Primary bioavailability parameters of loratadine in CYP2D6 extensive metabolizers

被引：0
|
作者：
Kunicki, PK
Gutkowski, P
机构：
[1] Natl Inst Cardiol, Dept Clin Biochem, Clin Pharmacol Unit, Warsaw, Poland
[2] TRIAL Clin Res Ctr, Warsaw, Poland
来源：
THERAPEUTIC DRUG MONITORING | 2003年 / 25卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
156
引用
收藏
页码：525 / 525
页数：1
相关论文
共 50 条
  • [21] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO EVALUATE THE SYSTEMIC EXPOSURE OF GEFITINIB IN THE CYP2D6 ULTRARAPID METABOLIZERS AND EXTENSIVE METABOLIZERS.
    Chen, Y.
    Zhou, W.
    Tang, W.
    Zhou, D.
    Masson, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S59 - S59
  • [22] Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers
    Güzey, C
    Spigset, A
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2006, 26 (02) : 211 - 212
  • [23] CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline
    Alfaro, CL
    Lam, YWF
    Simpson, J
    Ereshefsky, L
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (02) : 155 - 163
  • [24] Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers
    Begré, S
    von Bardeleben, U
    Ladewig, D
    Jaquet-Rochat, S
    Cosendai-Savary, L
    Golay, KP
    Kosel, M
    Baumann, P
    Eap, CB
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (02) : 211 - 215
  • [25] DNA HAPLOTYPE DEPENDENCY OF DEBRISOQUINE 4-HYDROXYLASE (CYP2D6) EXPRESSION AMONG EXTENSIVE METABOLIZERS
    MURA, C
    PANSERAT, S
    VINCENTVIRY, M
    GALTEAU, MM
    JACQZAIGRAIN, E
    KRISHNAMOORTHY, R
    HUMAN GENETICS, 1993, 92 (04) : 367 - 372
  • [26] Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects
    Damy, T
    Pousset, F
    Caplain, H
    Hulot, JS
    Lechat, P
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 (01) : 113 - 123
  • [27] Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites—a study in 839 patients with known CYP2D6 genotype
    Birgit M. Wollmann
    Elisabet Størset
    Marianne Kristiansen Kringen
    Espen Molden
    Robert L. Smith
    European Journal of Clinical Pharmacology, 2023, 79 : 523 - 531
  • [28] MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
    de la Torre, R
    Farré, M
    Mathúna, BO
    Roset, PN
    Pizarro, N
    Segura, M
    Torrens, M
    Ortuño, J
    Pujadas, M
    Camí, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (07) : 551 - 554
  • [29] MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
    Rafael de la Torre
    Magí Farré
    Brian Ó Mathúna
    Pere N. Roset
    Neus Pizarro
    Mireia Segura
    Marta Torrens
    Jordi Ortuño
    Mitona Pujadas
    Jordi Camí
    European Journal of Clinical Pharmacology, 2005, 61 : 551 - 554
  • [30] EFFECT OF PF299804 ON CYP2D6 ACTIVITY IN HEALTHY VOLUNTEERS (HVS) WHO ARE EXTENSIVE METABOLIZERS (EM)
    Bello, C. L.
    Labadie, R. R.
    Ni, G.
    Boutros, T.
    McCormick, C.
    Ndongo, N.
    ANNALS OF ONCOLOGY, 2010, 21 : 178 - 178
12345